Evidence map›Paper›PMID 25108100›Full record

ArticleImmunology letters2014

Blocking macrophage migration inhibitory factor activity alleviates mouse acute otitis media in vivo.

Jin Zhang, Min Xu, Qingyin Zheng, Yan Zhang, Weijun Ma, Zhaoqiang Zhang

Abstract read
In one paragraph

Article in Immunology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. A NovelInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Panel 3: Genomics, precision medicine and targeted therapies.International journal of pediatric otorhinolaryngology · 2020
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Panel 3: Genetics and Precision Medicine of Otitis Media.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jin ZhangDepartment of Otorhinolaryngology-HNS, The Second Affiliated Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an 710049, China.
Min XuDepartment of Otorhinolaryngology-HNS, The Second Affiliated Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an 710049, China. Electronic address: minxu_first@163.com.
Qingyin ZhengDepartment of Otolaryngology-HNS, Case Western Reserve University, Cleveland, OH 44106, USA.
Yan ZhangDepartment of Otorhinolaryngology-HNS, The Second Affiliated Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an 710049, China.
Weijun MaDepartment of Otorhinolaryngology-HNS, The Second Affiliated Hospital, Xi'an Jiaotong University, School of Medicine, Xi'an 710049, China.
Zhaoqiang ZhangDepartment of Otolaryngology-HNS, Case Western Reserve University, Cleveland, OH 44106, USA.
Second Affiliated Hospital of Xi'an Jiaotong University · CNCase Western Reserve University · US

Funding

Deciphering the Usher I protein interactome using a genetic approachR01DC009246 · NIDCD · CASE WESTERN RESERVE UNIVERSITY · PI ZHENG, QING Y · 2009 to 2013
$1.6M
Identify and Develop Mouse Models for Otitis MediaR21DC005846 · NIDCD · JACKSON LABORATORY · PI ZHENG, QING Y · 2003 to 2005
$562k
NIDCD NIH HHS R01 DC009246NIDCD NIH HHS R21 DC005846
6 · The paper itself

Abstract

This study was to investigate the role of macrophage migration inhibitory factor (MIF) in mouse acute otitis media (AOM), we hypothesize that blocking MIF activity will relieve mouse AOM. A mouse AOM model was constructed by injecting lipopolysaccharide (LPS) into the middle ear of C57BL/6 mice through the tympanic membrane (TM). MIF levels were measured by real-time PCR (RT-PCR) and ELISA after LPS application. Normal or AOM mice were given PBS or ISO-1 (MIF antagonist) every day for 10 days and the hearing levels were determined by measuring auditory brainstem response (ABR) threshold. After the ABR test finished, H&E staining was conducted and the inflammation was also measured by detecting interleukin (IL)-1β, tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF) levels with RT-PCR and ELISA. TLR-4 expression was determined by western blotting and NF-κB activation was determined by electrophoretic mobility shift assays. Compared with the normal control, MIF levels in the middle ear of LPS-induced AOM mice were significant increased. The ABR results showed that mean ABR thresholds in ISO-1 treated AOM mice were significantly reduced compared with PBS treated AOM mice since day 7, indicating that ISO-1 treatment potentially improved the hearing levels of AOM mice. H&E staining showed that ISO-1 treatment could reduce the mucosal thickness of AOM mice. In ISO-1 treated mice, TLR-4 expression and levels of IL-1β, TNF-α and VEGF were significantly lower compared with PBS treated AOM mice. ISO-1 treatment also significantly inhibited NF-κB activation in AOM mice compared with PBS treated AOM mice. These results suggested that blocking the activity of MIF by ISO-1 could reduce the inflammation in AOM mice in which process TLR-4 and NF-κB were involved. The reduction in MIF activity is conducive to alleviate mouse AOM, which may serve as a potential therapeutic target for the treatment of AOM.

Indexed as

AnimalsAuditory ThresholdEvoked Potentials, Auditory, Brain StemIsoxazolesLipopolysaccharidesMacrophage Migration-Inhibitory FactorsMaleMiceNF-kappa BOtitis MediaToll-Like Receptor 43-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl esterIsoxazolesLipopolysaccharidesMacrophage Migration-Inhibitory FactorsNF-kappa BToll-Like Receptor 4AOMIL-1βISO-1MIFTNF-αVEGF

Identifiers

PMID25108100
PMCPMC4252730
OpenAlexW2050641977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.